Nalaganje...
Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status
BACKGROUND: Patients with non-dialysis-dependent chronic kidney disease (ND-CKD) often receive an erythropoiesis-stimulating agent (ESA) and oral iron treatment. This study evaluated whether a switch from oral iron to intravenous ferric carboxymaltose can reduce ESA requirements and improve iron sta...
Shranjeno v:
| izdano v: | PLoS One |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Public Library of Science
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4415953/ https://ncbi.nlm.nih.gov/pubmed/25928811 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0125528 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|